129 related articles for article (PubMed ID: 25785139)
1. P53 mutations occur more commonly than KRAS mutations in colorectal adenoma.
Yan WF; Wu G; Sun PC; Qiu D
Int J Clin Exp Med; 2015; 8(1):1370-5. PubMed ID: 25785139
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas.
van Wyk R; Slezak P; Hayes VM; Buys CH; Kotze MJ; de Jong G; Rubio C; Dolk A; Jaramillo E; Koizumi K; Grobbelaar JJ
Genes Chromosomes Cancer; 2000 Feb; 27(2):202-8. PubMed ID: 10612810
[TBL] [Abstract][Full Text] [Related]
3. Different mutation profiles associated to P53 accumulation in colorectal cancer.
López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
5. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
7. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
Du L; Kim JJ; Shen J; Chen B; Dai N
Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
[TBL] [Abstract][Full Text] [Related]
8. Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.
Molnár B; Galamb O; Péterfia B; Wichmann B; Csabai I; Bodor A; Kalmár A; Szigeti KA; Barták BK; Nagy ZB; Valcz G; Patai ÁV; Igaz P; Tulassay Z
BMC Cancer; 2018 Jun; 18(1):695. PubMed ID: 29945573
[TBL] [Abstract][Full Text] [Related]
9. Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: association with morphological and prognostic criteria.
Samara M; Kapatou K; Ioannou M; Kostopoulou Ε; Papamichali R; Papandreou C; Athanasiadis A; Koukoulis G
Genet Mol Res; 2015 Dec; 14(4):16793-802. PubMed ID: 26681025
[TBL] [Abstract][Full Text] [Related]
10. KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
Gao W; Jin J; Yin J; Land S; Gaither-Davis A; Christie N; Luketich JD; Siegfried JM; Keohavong P
Mol Carcinog; 2017 Feb; 56(2):381-388. PubMed ID: 27182622
[TBL] [Abstract][Full Text] [Related]
11. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
13. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
15. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
16. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
[TBL] [Abstract][Full Text] [Related]
17. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
[TBL] [Abstract][Full Text] [Related]
18. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
[TBL] [Abstract][Full Text] [Related]
19. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
20. Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions.
Igder S; Mohammadiasl J; Mokarram P
Biochem Genet; 2019 Dec; 57(6):767-780. PubMed ID: 30997628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
